In spite of the fact that cyclin-dependent kinase (cdk) inhibiting drugs are potent transcriptional repressors, we discover that p57 (Kip2, CDKN1C) transcription is significantly upregulated by three small molecule cdk inhibitors, including BMS-387032. Treatment of MDA-MB-231 breast cancer cells with BMS-387032 led to a stabilization of the E2F1 protein that was accompanied by significant increases in the p57 mRNA and protein. This increase did not occur in an E2F1-deficient cell line. An E2F1-estrogen receptor fusion protein activated the endogenous p57 promoter in response to hydroxytamoxifen treatment in the presence of cycloheximide. Luciferase constructs driven by the p57 promoter verified that upregulation of p57 mRNA by BMS-387032 is transcriptional and dependent on E2F-binding sites in the promoter. Expression of exogenous p57 significantly decreased the fraction of cells in S phase. Furthermore, p57-deficient MDA-MB-231 cell lines were significantly more sensitive to BMS-387032-induced apoptosis than controls. The results presented in this manuscript demonstrate that small molecule cdk inhibitors transcriptionally activate p57 dependent upon E2F1 and that this activation in turn serves to limit E2F1's death-inducing activity.
Introduction
A family of enzymes known as the cyclin-dependent kinases (cdks) governs the mammalian cell cycle (Meyerson et al., 1992) . The activities of the cdks are subjected to positive regulation by association with cyclins and by negative regulation by two families of inhibitory proteins. The CDKN1 family contains three members A, B and C, which are more commonly referred to as p21 CIP1 (Harper et al., 1993 )/WAF1-(el-Deiry et al., 1993 , p27 KIP1 (Polyak et al., 1994; Toyoshima and Hunter, 1994 ) and p57 KIP2 (Lee et al., 1995; Matsuoka et al., 1995) . The second family of cdk inhibitors are the smaller CDKN2 proteins (p15, p16, p18 and p19), which are more commonly known as the inhibitor kinase 4A (INK4A) family (Sherr and Roberts, 1999) . Although, all cyclin-cdk activities may not be absolutely required for cell cycle progression (Geng et al., 2003; Ortega et al., 2003; Tetsu and McCormick, 2003) , genetic evidence strongly supports the idea that upregulation of cdks and the subsequent disruption of Rb/E2F complexes generally represent oncogenic events (Nevins, 2001) , whereas kinase inhibitory molecules represent tumor suppressor activities (Jackson et al., 2002 (Jackson et al., , 2003 . As such, this pathway is potentially an excellent target for the development of anti-cancer drugs (Shapiro, 2006) .
The role of cdks is not limited to the control of cell cycle as the name might imply. The cdk7-containing cyclin activating kinase (CAK) complex is a component of the multi-subunit transcription factor IIH (TFIIH), which phosphorylates the serine 5 of the heptapeptide repeat of RNA polymerase II large subunit promoting transcription initiation, promoter clearance and recruitment of the capping enzyme (Shapiro, 2006) . Cdk 9 forms a complex with cyclin T, which preferentially phosphorylates ser 2 of the heptapeptide repeat of RNA polymerase II large subunit promoting transcription elongation and recruitment of the 3 0 RNA processing activities (Shapiro, 2006) . Thus, small molecule cdk inhibitor drugs that aim to regulate cell cycle also inhibit general transcription (Lam et al., 2001) and it is likely that the rapid loss of survival genes having unstable mRNAs may contribute to apoptosis (Shapiro, 2006) . Although general transcription is inhibited by small molecule cdk inhibitors, a small number of transcripts are found to be upregulated by cdk inhibitors (Lu et al., 2004) .
In past work, we and others have found that the E2F1 protein is potently upregulated following treatment with several small molecule cdk inhibitors and that E2F1 deficiency provides resistance to cell death induced by these drugs (Matranga and Shapiro, 2002; Jiang et al., 2003; Ma et al., 2003a) . In contrast, these drugs repress E2F4 and E2F4 deficiency significantly increases cell death induced by cdk inhibitors . In the current work, we have further examined the effects of cdk inhibitors on the regulation of cell cycle genes. Most cell cycle regulated genes examined were silenced after treatment with BMS-387032. Surprisingly, we find one exception to this rule, p57 Kip2. A number of lines of evidence demonstrate that induction of p57 is transcriptional and is dependent on E2F1. Furthermore, data suggest that upregulation of p57 following BMS-387032 treatment primarily represents a feedback pathway that limits cell death. These finding suggest that cdk inhibitors can transcriptionally activate certain cellular targets in spite of the fact that they are general transcriptional inhibitors.
Results
To determine the effects of cdk inhibitors on the expression of key E2F and cell cycle associated transcripts, we performed RNase protection assays (RPAs) on various cell lines treated with various cdk inhibitor schedules. Data in Figure 1a highlight an example in which MDA-MB-231 cells were treated with 500 nM BMS-387032. Consistent with cdk inhibition, most of the potential E2F regulated transcripts, Rb (Shan et al., 1994) , p107 (Zhu et al., 1995) , p21 (Hiyama et al., 1997) , p27 (Wang et al., 2005) , cyclin A (Schulze et al., 1995) and the tightly autoregulated E2F1 mRNA (Johnson et al., 1994) were silenced in spite of a great increase in the amount of E2F1 protein. Likewise, the p53 and cdk4 mRNAs, which are not E2F1-regulated, were also diminished by BMS-387032 treatment. In contrast, the p57 mRNA was potently activated by BMS-387032 treatment coincident with the induction of E2F1 protein at 12-18 h post-treatment. Western blots BMS-387032 regulates p57 via E2F1 Y Ma and WD Cress shown in Figure 1a further reveal that the induction of the p57 mRNA in turn leads to a significant increase in the p57 protein by 24 h. This activation of p57 mRNA occurs in spite of the fact that 500 nM BMS-387032 blocked the phosphorylation of Ser 2 and Ser 5 of the RNA Polymerase II C-terminal domain (Pol II CTD) as evidenced by Western blots using phosphopeptidespecific antibodies (Figure 1a , bottom) presumably inhibiting most RNA Pol II-driven transcription. Figure 1b reveals that roscovitine and flavopiridol also induce p57. The correlation between E2F1 protein accumulation and p57 mRNA suggested that E2F1 might regulate p57. To test this, MDA-MB-231 cells were infected with an E2F1-expressing adenovirus and the E2F1 and p57 mRNAs and proteins were measured as a function of time. Figure 1c reveals that the p57 mRNA and protein are both induced within 24 h of Ad-E2F1 infection. Previous work has shown that p21 Cip (Gartel et al., 1998 (Gartel et al., , 2000 and p27 Kip1 (Wang et al., 2005) can be transcriptionally activated by E2F1 via direct promoter interaction. The data in Figure 1a -c would be consistent with a model in which the stabilization of the E2F1 protein by BMS-387032 leads to the activation of the p57 promoter either directly or indirectly. E2F1 has been shown to transcriptionally activate p73 transcription (Irwin et al., 2000; Stiewe and Putzer, 2000) . Independent studies have shown that p73 can activate p57 expression by an unexplored mechanism (Balint et al., 2002; Merlo et al., 2005) . To determine if p73 might play a role in BMS-387032 induction of p57, we utilized quantitative PCR to measure the amount of p73 mRNA following BMS-387032 treatment or treatment with an E2F1 adenovirus as a positive control. Figure 1d makes it apparent that p73 mRNA is readily induced by the E2F1 virus, but not by BMS-387032. Thus, E2F1-mediated upregulation of p73 cannot account for the induction of p57 by BMS-387032.
To rule out the possibility that E2F1 might activate the p57 promoter by an indirect mechanism, we turned to a series of previously described H1299 derivatives (Ma et al., 2003a (Ma et al., , b, 2004 having various proficiencies and deficiencies in E2F1 expression. Figure 2a reveals that parental H1299 cells express relatively low levels of endogenous p57, however, infection with an AdE2F1-expressing adenovirus results in significant induction of the p57 mRNA and protein. To determine if activation of p57 by E2F1 could be direct, we utilized an H1299 cell line derivative (Ma et al., 2003b ) that constitutively expresses an estrogen receptor-E2F1 fusion protein (ER-E2F1) (Vigo et al., 1999) . The ER-E2F1 fusion cell line and a control line were treated with dimethylsulfoxide solvent only (DMSO), with cycloheximide (CHX) alone, 2-hydroxytamoxifen (OHT) alone or a combination of both CHX and OHT. RPAs, shown in Figure 2b , reveal that the p57 mRNA levels increased in the presence of OHT alone and increased dramatically in the presence of both OHT and CHX. Western blots, shown in Figure 2c , reveal that the p57 protein was also induced in the presence of OHT. Levels of p57 mRNA and protein did not change in response to OHT in the control cell line. These results demonstrate that p57 is a direct target of E2F1.
To determine if the upregulation of p57 by BMS-387032 was dependent on E2F1 we treated an E2F1-deficient H1299 cell line with BMS-387032 and examined p57 mRNA levels by RPA. The results, shown in the right panel of Figure 3a , reveal that deficiency of E2F1 ablates upregulation of p57 following BMS-387032 treatment. Western blots analysis revealed a similar effect on p57 protein levels ( Figure 3b ).
To better understand the mechanism by which BMS-387032 leads to upregulation of p57 we transfected H1299 cells with reporter vectors driven by different subclones of the human p57 promoter (Alheim et al., 2003) . The data (Figure 4a ) reveal that each p57
Figure 2 E2F1 upregulation of the p57 promoter is direct.
(a) H1299 cells were infected with the indicated adenoviral expression vectors at a MOI of 10 (based upon plaque assay), or as specifically indicated. At 48 h after infection extracts were harvested and subjected to RPA or Western blots. (b) H1299 control cells or a derivative expressing ER-E2F1 was subjected to OHT (4-hydroxytamoxifen, 300 nM) added to medium to induce ER-E2F1 nuclear accumulation. CHX was used at a final concentration of 10 mg/ml to inhibit new protein synthesis. Cells were harvested after 24 h and p57 mRNA evaluated by RPA as described above. (c) Same as in (b), except a Western blot was performed following OHT treatments. The lower p57 band may represent an alternatively spliced p57 mRNA (Lee et al., 1995) . CHX-treated cells were not including in panel C since p57 protein could not accumulate in its presence.
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promoter reporter was activated by BMS-387032 or by E2F1. In contrast, two typical E2F regulated genes, the adenovirus E2 promoter (Kovesdi et al., 1987) and the cyclin D3 promoter (Ma et al., 2003b) , were not significantly activated by BMS-387032. Examination of the sequence of the p57 promoter revealed three potential binding sites for E2F1 (Figure 4b ). To determine if the BMS-387032 induction of the p57 promoter was dependent upon E2F-binding sites, construct p57 À110/ þ 15 that lacks all three potential E2F-binding sequences, was assayed. This construct retains 42% of the basal activity of the À1552/ þ 14 promoter, but it does not respond to BMS-387032 or E2F1 (Figure 4c ). To determine if the activation of the p57 promoter was indeed dependent on E2F1, we compared the BMS-387032 response of the À1025/ þ 14 construct in H1299 cells and in H1299 derivates deficient in E2F1. The data ( Figure 4d ) reveal that activation of the p57 reporter by BMS-387032 depends These cell lines were previously derived and characterized (Ma et al., 2003a . At the indicated times after drug treatment RNA was harvested and RPAs (a) or Western blots (b) performed. Figure 4e , a series of E2F family expression vectors are compared for the ability to activate the À1025/ þ 14 promoter. E2F1 appears to be the most potent inducer of p57.
BMS-
To test the possibility that E2F1-mediate induction of p57 might negatively feedback to repress E2F1-driven transcription, a p57 expression vector was co-transfected together with E2F1 and the autoregulated E2F1 promoter/reporter (Johnson et al., 1994; Johnson, 1995) . The results in Figure 5a reveal that E2F1 potently activates its own promoter and that this activation is diminished by coexpression of p57. Inhibition of E2F-driven transcription would be expected to reduce progression into S phase. To test this, asynchronous H1299, MCF-7 and T98G cells were transfected with a p57 expression vector, pCMV-p57, along with a surface green fluorescent protein (GFP) expression vector (pBB14) to mark-transfected cells. Expression of exogenous p57 is evident in Western blots of transfected cells (see Figure 5b ). Figure 5c reveals that p57 expression reduced the number of T98G cells in S phase by more than half and the number of MCF-7 cells in S phase by approximately one-third. Reduction of H1299 cells in S phase was modest, but differences were statistically significant. To determine if p57 could inhibit endogenous E2F-regulated genes H1299 and T98G cells were infected with the Ad-p57 virus or with a control GFP-expressing adenovirus. Figure 5d reveals that the viral vector expresses abundant p57 and that ectopic p57 significantly diminishes the number of cells in S phase. Furthermore, the p57 virus significantly inhibits E2F1 expression. These results clearly support the idea that p57 can negatively regulate E2F1 as it blocks cell cycle progression.
To investigate the biological role of p57 induction by BMS-387032, we used an RNA inhibitor approach to develop four stable MDA-MB-231 derivative cell lines that express diminished levels of p57 (see Supplementary Material for a description of these lines). Figure 6a demonstrates that all four p57-knockdown cell lines express significantly less p57 than the parental cell line both before and after treatment with BMS-387032. E2F1 levels, before and after BMS-387032 treatment, are not detectably affected by p57 deficiency. Likewise, Figure 6b demonstrates that p57 deficiency has only a modest affect on growth rate or saturation density suggesting that endogenous p57 is not a major determinant of the growth rate or survival of the cells under investigation in the absence of drug treatment. To determine if p57 deficiency would affect cellular response to BMS-387032, cells were treated with the drug and cell cycle properties and apoptosis was measured by FACS. Figure 7a . Western blots and cell cycle analysis were performed after 48 h. p57 induced changes in G1/G0 and S phase are statistically significant (Po0.05).
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greater in all four p57-deficient lines than control cells indicating a significant increase in apoptosis. In fact, the sub-G1 content observed in the p57-deficient cells was so high that it made the determination of cell cycle phases unreliable. To confirm that the sub-G1 DNA observed in p57-deficient cells was due to apoptosis terminal deocynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)-staining using an ApoBrdU kit (PharMingen, San Diego, CA, USA) that is a more direct and sensitive measure of apoptosis were also performed, as shown in Figure 7b . As a positive control the parental cell line and the four derivative lines were infected with an E2F1-expressing adenovirus. Figure 7c demonstrates that the four cell lines do not differ from controls regarding sensitivity to E2F1-induced death. This indicates that the control cell line is not unexpectedly resistant to apoptosis. Taken together, the results demonstrate that upregulation of p57 following drug treatment has a strong antiapoptotic effect.
Discussion
In the current work, we have shown that E2F1 is a direct and potent regulator of the p57 promoter and that E2F1
is necessary for BMS-387032 to induce p57 mRNA. As E2F1 is known to activate transcription of the p73b promoter (Irwin et al., 2000) , it is possible that p73 contributes to E2F1 upregulation of p57 (Balint et al., 2002) . However, p73 does not appear necessary for E2F1-mediated regulation of p57 since a pre-existing ER-E2F1 fusion protein can induce the endogenous p57 promoter even in the presence of CHX, upon the addition of OHT. Likewise, we find no evidence of upregulation of p73 following treatment with BMS-387032. Considered together with other recent work, the results presented herein indicate that all three members of the CDKN1 family are direct E2F1 targets (Gartel et al., 1998 (Gartel et al., , 2000 Wang et al., 2005) . We consider three likely pathways to account for the functional relevance of p57 induction by E2F1. The first proposes that p57 BMS-387032 regulates p57 via E2F1 Y Ma and WD Cress induction contributes to E2F1-induced apoptosis. This model emerges from recent work (by others) that has shown that p73b-induced apoptosis involves p57 induction and that it can be blocked by RNAis targeting p57 (Gonzalez et al., 2005) . Likewise, it has been shown that ectopic p57 sensitizes HeLa cells to staurosporineinduced cell death (Samuelsson et al., 2002) . This model is not supported by our work since we did not see evidence that p57 overexpression resulted in significant apoptosis in the cell lines examined (not shown). Furthermore, our p57 RNAi results suggest that p57 is antiapoptotic. These results are not necessarily contradictory since it is possible that p57 is necessary for p73-induced apoptosis, which we have not examined. A second possibility is that p57 may play an important role in mitotic exit and reentry into G1. It has been shown that p57 mRNA is induced at the M-G1 transition and that functional knockdown of p57 gene expression by small interfering RNAs alters mitotic progression, yielding an increase of ana-telophase cells, the accumulation of late mitotic figures and the appearance of abnormalities in the subsequent interphase (Merlo et al., 2005) . E2F1 has been found to regulate a number of genes that are thought to have specific mitotic roles (Ishida et al., 2001; Ma et al., 2002) . Perhaps p57 represents one of a number of E2F1 cell cycle targets that mediates an effect on M-G1. In our experiments, we clearly detect a reduction of G2/M cells upon overexpression of p57. Future work will examine whether p57 mediates an essential role for E2F in mitosis.
A third model, which does not necessarily exclude the others, focuses on the known function of p57 as an inhibitor of E2F1-driven transcription. In this model, we would propose that E2F1 induction of p57 serves as a negative feedback loop that restrains excessive E2F1 activity. Our results clearly provide strong support this model -in that -overexpression of p57 restrains E2F1-driven transcription and results in reduced S phase fraction. More importantly our results demonstrate that p57-deficient cells are greatly sensitized to BMS-387032-induced cell death clearly supporting the hypothesis that this pathway serves as a negative feedback loop to promote survival.
The relevant targets of p57, in cells treated with BMS-387038, remains an open question. As the cdks should largely be inhibited by the drug itself, it seems unlikely that inhibition of cdks is the primarily mechanism by which p57 promotes cell survival. Based on the literature we would propose that p57 may inhibit E2F1-driven transcription in a manner that does not require cdk inhibition. This model is not novel since a cdk/Rbindependent mechanism of E2F feedback has been well described for p21 (Delavaine and La Thangue, 1999) . It was shown that p21 could inhibit an E2F-driven promoter and that it could be found stably associated with E2F complexes, which at the time was presumed to involve a complex including E2F/Rb/cyclin/cdk2 with the association with E2F mediated by the cyclin/cdk2 bridge (Afshari et al., 1996) . It has been shown that GST-p21 can bind to E2F1 and Dp1, and that p21 can inhibit transcription of a Gal4-E2F fusion in reporter assays in vivo and in a general transcription assay in vitro (Delavaine and La Thangue, 1999) . A notable deficiency of this early work is that there was no examination of endogenous complexes, however, a recent study has used chromatin immunoprecipitations assays to demonstrate that p21 is associated with the Wnt4 promoter (Devgan et al., 2005) . Future work will address how p57 represses E2F1-driven transcription and BMS-387032-induced apoptosis.
Materials and methods
A more detailed description of Materials and methods is provided in the Supplementary Material.
Cell lines, plasmids and viruses
All cell lines were obtained from the ATCC. H1299 cells were cultured in Dulbecco's modified Eagle's media (DMEM) supplemented with 5% fetal bovine serum (FBS). MCF-7, MDA-MB-231 and T98G cells were grown in DMEM with 10% FBS. MDA-MB-231 cell lines lacking p57 expression were generated by shRNA as described in the Supplementary Material. The human p57 promoter reporters (Alheim et al., 2003) were a kind gift from Dr Okret (Karolinska Institute, Stockholm, Sweden). The pBB14 expression vector for membrane GFP (Brideau et al., 1998; Kalejta et al., 1999) was a kind gift from Dr Enquist (Princeton). An expression vector for p57 was purchased (pCMVp57, CAT no. TC127869, Origene Technologies). NCI CTEP provided flavopiridol; Bristol-Myers Squib provided BMS-387032, and roscovitine was purchased from Sigma (St Louis, MO, USA). All drug treatments were performed as previously described and unless otherwise noted BMS-387032 treatment was 500 nM. Dr Matthew Stewart (University of Illinois at UrbanaChampaign, Urbana, IL, USA) provided Adp57 virus (Stewart et al., 2004) . Dr Haura (Moffitt Cancer Center) provided Ad-GFP, an adenoviral vector expressing the GFP, which was used as a negative control. AdT-E2F1, an adenovirus expressing GFP and E2F1, was generated using the AdEasy system (Quantum Biotechnologies, Montreal, Canada). For AdT-E2F1 and Ad-GFP experiments viral titers were determined on 293 cells using plaque assay (Ma et al., 2002) . GFP expression by the AdT-E2F1 and Ad-GFP viruses was verified by fluorescent microscopy. For Ad-p57 (no GFP) and Ad-GFP experiments we utilized an Adeno-X Rapid Titer Kit (BD Biosciences 631028, San Jose, CA, USA) to equalize virus infections. Western blots verified viral expression of E2F1 or p57 and absence of E1A expression (to ensure non-recombination). Unless otherwise noted viral infections were performed using a multiplicity of infection (MOI) of ten viruses per cell.
Cell cycle and apoptosis analysis Cells were co-transfected with pBB14 (GFP) and pCMV-p57, or pcDNA3 as control, using calcium phosphate. After transfection, floating cells were collected and adherent cells were dislodged using Accutase. Cells were pooled, washed and fixed with ice-cold 70% ethanol. Fixed cells were washed and resuspended in PBS containing RNase A and propidium iodide (PI). GFP-positive cells were gated for cell cycle and sub-G1 DNA content analysis using Becton-Dickinson (Mountain View, CA, USA); FACScan instrument and Cell Quest software. Apoptosis was assayed using Pharmingen APO-BRDU Kit without modification.
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Biochemical assays
Transfections for luciferase assay were performed using calcium phosphate with various DNAs totaling 2 mg of DNA per well in a 12-well dish. Cells were harvested 48 h after transfection and luciferase assays were performed using the Dual-Luciferase Reporter Assay System following the manufacturer's protocol (Promega, Madison, WI, USA). In some cases, transfected cells were treated with 500 nM BMS-386032 for 24 h before harvest. RNA protection assays were performed using the Riboquant multi-probe template HCC-2 (Cat no. 556160) from PharMingen. Western blots were performed as previously described (Ma et al., 2003a (Ma et al., , b, 2004 using an E1A monoclonal antibody (Pharmingen, 14161A), an E2F1 monoclonal (sc-251, Santa Cruz), a human p57 polyclonal (sc-1040, Santa Cruz), a mouse p57 polyclonal (sc-8298, Santa Cruz), a cdk4 monoclonal (Pharmingen, 68791A) a cyclin A monclonal (provided by Dr Jack Pledger, Moffitt Cancer Center, Tempa, FL, USA) or an actin monoclonal antibody (A5441, Sigma). Three monoclonal antibodies, 8WG16, H5 and H14, against the RNA Polymerase II large subunit were also utilized (Covance Research Products, Berkeley, CA, USA). Antibody 8WG16 recognizes the RNA Pol II C-terminal heptapeptide repeat regardless of modification. Antibodies H5 and H14 recognize RNA Pol II C-terminal heptapeptide repeat phosphorylated at Ser 2 (by Cdk9) and Ser 5 (by Cdk7), respectively.
